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Abstract
Purpose: This systematic review and meta-analysis aimed to quantify the diagnostic
performance of pancreatic venous sampling (PVS), selective pancreatic arterial calcium
stimulation with hepatic venous sampling (ASVS), and 18F-DOPA positron emission tomography
(PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI).
Procedures: This systematic review and meta-analysis was conducted according to the PRISMA
statement. PubMed, EMBASE, SCOPUS and Web of Science electronic databases were systemat-
ically searched from their inception to November 1, 2011. Using predefined inclusion and exclusion
criteria, two blinded reviewers selected articles. Critical appraisal ranked the retrieved articles according
to relevance and validity by means of the QUADAS-2 criteria. Pooled data of homogeneous study
results estimated the sensitivity, specificity, likelihood ratios and diagnostic odds ratio (DOR).
Results: 18F-DOPA PET was superior in distinguishing focal from diffuse CHI (summary DOR,
73.2) compared to PVS (summary DOR, 23.5) and ASVS (summary DOR, 4.3). Furthermore, it
localized focal CHI in the pancreas more accurately than PVS and ASVS (pooled accuracy, 0.82
vs. 0.76, and 0.64, respectively). Important limitations comprised the inclusion of studies with
small sample sizes, high probability of bias and heterogeneity among their results. Studies with
small sample sizes and high probability of bias tended to overestimate the diagnostic accuracy.
Conclusions: This systematic review and meta-analysis found evidence for the superiority of 18F-
DOPA PET in diagnosing and localizing focal CHI in patients requiring surgery for this disease.
Key words: Congenital hyperinsulinism, Pancreatic venous sampling, Arterial stimulation
venous sampling, 18F-DOPA PET, Positron emission tomography, Diagnosis
Introduction
C ongenital hyperinsulinism (CHI) represents a hetero-geneous group of genetic disorders characterized by
excessive insulin secretion for the level of glycaemia [1–
3]. Up to 60 % of CHI patients fail to respond to dietary
and medical measures and require surgical pancreatecto-
my to remain normoglycaemic [4–6]. The extent of
pancreatectomy performed depends on the histopatholog-
ical diagnosis: focal or diffuse disease [7]. Focal islet-
cell hyperplasia can be cured by focal excision of the
lesion [8, 9]. Diffuse β-cell hypersecretion requires near-Correspondence to: Abass Alavi; e-mail: abass.alavi@uphs.upenn.edu
total pancreatectomy, is only palliative, and may result in
diabetes mellitus and/or exocrine pancreas insufﬁciency
[4, 10, 11]. Therefore, it proves crucial to differentiate
focal from diffuse disease before surgery is commenced
[12]. Furthermore, preoperative localization of focal
disease in the pancreas (i.e. distinction between pancre-
atic head, body, or tail) can help paediatric surgeons
considerably in identifying the macroscopic indiscernible
focal lesion from non-affected pancreatic tissue during
curative surgery.
Because clinical presentation, genetic testing, and
structural imaging methods such as ultrasound, computed
tomography (CT), and magnetic resonance imaging
(MRI) are usually non-discriminatory for the purpose of
diagnosing and localizing focal CHI [1], interventional
radiologic tests, such as pancreatic venous sampling
(PVS) and combined selective pancreatic arterial calcium
stimulation and hepatic venous sampling (ASVS), have
been developed [13–16]. In addition, ﬂuorine-18 labelled
ﬂuoro-L-DOPA (18F-DOPA) positron emission tomogra-
phy (PET) imaging has been proposed as a technique to
identify and localize focal disease [17, 18]. However, the
diagnostic accuracy of each of these modalities has not
been well established.
Therefore, the purpose of this article was to provide the
best available evidence on the diagnostic accuracy of PVS,
ASVS, and 18F-DOPA PET in diagnosing and localizing a
focal subtype of CHI in patients requiring surgery for this




This systematic review and meta-analysis was conducted according
to the PRISMA statement [19].
Search Strategy
Using predeﬁned search terms, the PubMed, EMBASE, SCO-
PUS and Web of Science electronic databases were systemat-
ically searched from inception to November 1, 2011. The
search syntax is presented in Table 1. No search ﬁlters or
language restrictions were imposed. A cross-reference check of
included articles was used to identify additional articles missed
by our search strategy.
Eligibility Criteria
Two blinded reviewers assessed article eligibility using pre-
deﬁned inclusion and exclusion criteria. Relevant articles were
included based on the following criteria: study domain—
patients with CHI; index test—PVS, or ASVS, or 18F-DOPA
PET; reference standard—histopathology obtained from surgery;
study results—agreement between index and reference standard;
study design—cross-sectional study format. In case of multiple
studies reporting on an overlapping population, only the study
with the largest patient population was included. Probability
adjusted agreement (κ statistic) evaluated interrater agreement
[20]. Discordant judgments were resolved by consensus
discussion.
Critical Appraisal
Two blinded reviewers appraised the relevance and validity of
the selected papers by use of the revised Quality Assessment of
Studies of Diagnostic Accuracy Included in Systematic Reviews
(QUADAS-2) criteria [21]. The item ‘ﬂow and timing’ was
replaced by ‘missing data’ because the question “was there an
appropriate interval between the index test and reference
standard” was considered not meaningful since CHI is a long-
standing genetic disease [22]. Furthermore, the item ‘blinding’
was presented separately to reﬂect its importance in bias
assessment of diagnostic studies. Six authors were contacted
to provide data on sufﬁcient blinding protocols. Five authors
responded and provided the requested data. The κ statistic
evaluated interrater agreement. Discordant judgments were
resolved by consensus discussion.
Data Extraction
The following data were extracted from included articles: study
design, study population, index test characteristics, reference
standard characteristics, and localization accuracy. Furthermore,
true positive, false-positive, true negative and false-negative rates
were extracted and summarized in 2×2 contingency tables. Empty
cells were ﬁlled with 0.5 events to allow calculation of the outcome
measures of interest.
Outcome Measures and Data Synthesis
Calculating the sensitivity, speciﬁcity, positive and negative
likelihood ratio (LR), and the diagnostic odds ratio (DOR)
along with 95 % conﬁdence intervals determined the diagnostic
accuracy of each index test in differentiating focal from diffuse
CHI. The percentage of tests that localised the focal lesion in
the correct area of the pancreas according to histopathology
determined the localisation accuracy. Inability to detect focal
CHI was considered a failed attempt to localise the focal
lesion.
Heterogeneity was determined statistically by a Cochran Q
(χ2 statistic) test and the Ι2 statistic for heterogeneity. An Ι2
statistic of 925 % was considered evidence for clinically relevant
heterogeneity [23]. In case of clinically relevant heterogeneity,
outcome measures were estimated from studies of the highest
scientiﬁc validity—that is, studies that are most likely to be free
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from bias. Data from statistically homogenous studies were
pooled by means of a random-effects model (DerSimonian–
Laird) to estimate outcome measures. Furthermore, pooled data
was used to determine the area under the ROC curve (AUC) and
the Q* statistic.
The presence of possible publication bias was evaluated
graphically by drawing funnel plots for each outcome measure
and statistically by means of Egger’s standard regression test.
Statistical signiﬁcance was claimed for pG0.10 (two-tailed). We
acknowledge that other factors, such as methodological heteroge-
neity or true study heterogeneity, could also introduce asymmetry
in publication bias assessment [24].
Data analysis was performed using the publically available
dedicated meta-analysis software-tool Meta-DiSc version 1.4 [25].
Results
After adjusting for duplicates, our systematic search
retrieved 1,487 possibly relevant articles. Thirteen articles
(excluding ﬁve with overlapping patient populations [12, 14,
17, 18, 26]) met our predeﬁned criteria and were selected for
inclusion with very high interrater agreement (κ00.92)
(Fig. 1).
Table 1. Search syntax
Database Search syntax
PubMed (“hyperinsulinism”[TIAB] OR “CHI”[TIAB] OR “nesidioblastosis”[TIAB] OR “islet cell”[TIAB] or “beta cell”[TIAB] OR
“hypoglycemia”[TIAB] OR “PHHI”[TIAB] OR “HHI”[TIAB] OR “HI”[TIAB] OR “ insulinoma”[TIAB] OR
“hyperinsulinaemic”[TIAB] OR “hyperinsulinemic”[TIAB]) AND (“positron emission tomography”[TIAB] OR “PET”[TIAB] OR
“18F-DOPA”[TIAB] OR “18F-ﬂuoro-L-DOPA”[TIAB] OR “ﬂuorine-18-L-3,4-dihydroxyphenylalanine”[TIAB] OR “venous
sampling”[TIAB] OR “PVS”[TIAB] OR “calcium stimulation”[TIAB] OR “PACS”[TIAB] OR “ASVS”[TIAB] OR “vein
catherization”[TIAB] OR “PPVC”[TIAB] OR “THPVS”[TIAB])
EMBASE Replaced [TIAB] with :ab,ti
SCOPES Replaced [TIAB] by search ﬁeld: Article Title, Abstract, Keywords

































- Case reports (n = 21)
- Conference abstracts (n = 1)
- Reviews (n = 23)
- Studies with overlapping 
patient populations (n = 5)
- Full-text does not contain 
domein, determinant, and
outcome (n  = 27)
ASVS (n = 2)
 - Differentiation (n = 2)
 - Localization (n = 2)
PVS (n = 6)
 - Differentiation (n = 4)
 - Localization (n = 2)
18F-DOPA PET (n = 8)
 - Differentiation (n = 7)
 - Localization (n = 6)
Fig. 1. Flowchart of search strategy. Search performed on November 1st, 2011.
B.A. Blomberg et al.: Diagnosing and Localizing Focal CHI 99
Included trials were published between 1989 and 2011
and reported on a total of 415 patients with CHI (Table 2).
All studies had a cross-sectional study design. The value of
PVS was reported in six articles [7, 13, 27–30]. Of these,
four studies reported data on differentiation accuracy, two
reported data on localisation accuracy. The value of ASVS
was reported in two studies [16, 31]. Both reported data on
differentiation accuracy and localisation accuracy. Eight
articles reported data on the value of 18F-DOPA PET [27,
29, 30, 32–36]. Of these, one reported data on localisation
accuracy, two reported data on differentiation accuracy, and
ﬁve articles reported both.
Articles were ranked according to relevance and validity
with good interrater agreement (κ00.82). Potential threats to
relevance and scientiﬁc validity are summarized in Table 3.
Differentiation Accuracy
Table 4 shows the diagnostic accuracy of PVS, ASVS and
18F-DOPA PET differentiating focal and diffuse CHI.
Trials reporting on PVS included 65 patients. Pooled data
estimated a sensitivity of 0.87 (95 % CI; 0.70, 0.96), a
positive LR of 3.6 (95 % CI; 1.99, 11.9), and a negative LR
of 0.23 (95 % CI; 0.11, 0.52). Heterogeneity was present for
speciﬁcity (Ι2030 %, χ204.29, df03, p00.23). Graphically,
the trial from de Lonlay, et al. [7] stood out (speciﬁcity 0.73
vs. 1.00). The summary DOR of 23.5 (95 % CI; 6.1, 90.9)
was consistent across studies (Ι2, 0 %). The summary ROC
showed an AUC of 0.90 and a Q* of 0.83. These results
were consistent across studies (Ι2, 0 %; Fig. 2).
Two trials were identiﬁed that reported on ASVS and
included 60 patients. Heterogeneity was present for speci-
ﬁcity (Ι2054 %, χ202.18, df01, p00.14) and positive LR
(Ι2031 %, χ201.46, df01, p00.23) estimates. Pooled data
estimated a sensitivity of 0.71 (95 % CI; 0.55, 0.84) and a
negative LR of 0.93 (95 % CI; 0.26, 0.82). The estimate of
the summary DOR was 4.3 (95 % CI; 1.3, 14.7) and was
consistent across studies (Ι2, 0 %). The summary ROC
showed an AUC of 0.73 and a Q* of 0.67. These results
were homogenous across studies (Ι2, 0 %; Fig. 2).
Trials reporting on 18F-DOPA PET included 132
patients. Heterogeneity was observed for sensitivity (Ι20
50 %, χ2012.6, df06, p00.06). Graphically, the studies
from Hardy et al. [33] and Masue et al. [34] stood out.
Both studies underestimated the sensitivity compared to
the pooled estimate of the other studies (0.75 and 0.67
vs. 0.96). Pooled data estimated a speciﬁcity of 1.00
Table 2. Basic study characteristics of included articles in alphabetical order














NR NR 74 19 PVS 19 Histology 6 Differentiation Cross-sectional
Capito et al.
(2009) [27]
1995–2008 0 (0–9) 43 51 PVS 35 Histology 51 Localization Cross-sectional
18F-DOPA PET 16 Localization
Chigot et al.
(2001) [31]





1983–2000 NR 69 45 PVS 48 Immunohistochemistry 45 Localization Cross-sectional
de Lonlay et al.
(1999) [7]
1985–1998 NR 53 52 PVS 45 Histology 52 Differentiation/
localization
Cross-sectional
de Lonlay et al.
(2006) [29]
NR NR NR 7 PVS 4 Immunohistochemistry 7 Differentiation Cross-sectional
18F-DOPA PET/MRI 7 Differentiation
Hardy et al.
(2007) [33]





2005–2010 (2–37) 47 17 ASVS 7 Histology 12 - Cross-sectional
18F-DOPA PET/CT 17 Differentiation
Otonkoski et al.
(2006) [35]





NR (0–8) NR 49 PVS 12 Immunohistochemistry 24 Differentiation Cross-sectional









2006–2010 NR 42 19 18F-DOPA PET 19 Immunohistochemistry 19 Differentiation/
localization
Cross-sectional
CHI congenital hyperinsulinism; n1 number of patients; n2 number of index tests performed; n3 number of reference tests performed; NR not reported; CT
computed tomography; MRI magnetic resonance imaging; 18F-DOPA PET ﬂuorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography; PVS
pancreatic venous sampling; ASVS selective pancreatic arterial calcium stimulation with hepatic venous sampling
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(95 % CI; 0.93, 1.00), a positive LR of 9.49 (95 % CI;
3.5, 26), and a negative LR of 0.23 (95 % CI; 0.14,
0.37). The estimate of the summary DOR was 73.2
(95 % CI; 19.2–297.7) and was consistent across studies
(Ι2, 0 %). The summary ROC showed an AUC of 0.95
and a Q* of 0.90. These were also consistent across
studies (Ι2, 0 %; Fig. 2).
Localization Accuracy
Table 5 shows the localization accuracy of PVS, ASVS and
18F-DOPA PET.
Trials reporting on PVS included 80 patients. All
included studies were at risk for bias, but pooled data
showed homogeneity among their results (Ι200 %). Pooled
Table 3. Assessment of methodological quality and applicability; in order of relevance and validity
Author (year) Relevance Validity
Domain Index test Reference standard SDo SIT BRS SRS BIT MD
de Lonlay et al. (1999) [7] CHI PVS Histology + + − + − −
Brunelle et al. (1989) [13] CHI PVS Histology + + − − − −
de Lonlay et al. (2006) [29] CHI PVS Immunohistochemistry − − − + − −
Ribeiro et al. (2007) [30] CHI PVS Immunohistochemistry − + − − − −
Capito et al. (2009) [27] Focal CHI PVS Histology + + − + − +
Crétolle et al. (2002) [28] Focal CHI PVS Immunohistochemistry + + − + − +
Stanley et al. (2004) [16] CHI ASVS Histology + + + + + +
Chigot et al. (2001) [31] CHI ASVS Histology − + − + − −
Hardy et al. (2007) [33] CHI 18F-DOPA PET/CT Immunohistochemistry + + + + + +
Zani et al. (2011) [36] CHI 18F-DOPA PET/CT Immunohistochemistry + + ? + ? +
de Lonlay et al. (2006) [29] CHI 18F-DOPA PET/MRI Immunohistochemistry − + − + − +
Barthlen et al. (2008) [32] CHI 18F-DOPA PET/CT Immunohistochemistry − + + + + −
Masue et al. (2011) [34] CHI 18F-DOPA PET/CT Histology + + − ? − −
Ribeiro et al. (2007) [30] CHI 18F-DOPA PET/MRI Immunohistochemistry − + − ? − −
Otonkoski et al. (2006) [35] CHI 18F-DOPA PET Histology − + − ? − −
Capito et al. (2009) [27] Focal CHI 18F-DOPA PET Histology + + − + − +
CHI congenital hyperinsulinism; PVS pancreatic venous sampling; ASVS selective pancreatic arterial calcium stimulation with hepatic venous sampling; 18F-
DOPA PET ﬂuorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography; CT computed tomography; MRI magnetic resonance imaging; SDO
standardized selection of domain; + standardized, transparent and reproducible, bias unlikely; − no standardization, bias likely; SIT standardized assessment of
index test (IT); + standardized, transparent and reproducible, bias unlikely; − no standardization, bias likely; BRS blinding outcome of RS for assessor of IT;
blinding, + bias unlikely; − no blinding, bias likely; SRS standardized assessment of reference standard (RS); + standardized transparent and reproducible, bias
unlikely; − no standardization, bias likely; BIT blinding outcome of IT for assessor of RT; + blinding, bias unlikely; − no blinding, bias likely; MD missing
data, including veriﬁcation bias; + missing G10 %, bias unlikely; − missing data 910 %, bias likely
Table 4. Diagnostic accuracy; in order of relevance and validity










de Lonlay et al. (1999) [7] PVS 45 0.90 (0.70, 0.99) 0.73 (0.52, 0.88) 3.3 (1.7, 6.4) 0.14 (0.04, 0.55) 32.1 (4.2, 126.6)
Brunelle et al. (1989) [13] PVS 6 1.00 (0.29, 1.00) 1.00 (0.29, 1.00) 7.0 (0.51, 96.1) 0.14 (0.01, 1.96) 49.0 (0.74, 3237)
de Lonlay et al. (2006) [29] PVS 4 1.00 (0.16, 1.00) 1.00 (0.16, 1.00) 5.0 (0.38, 66.0) 0.20 (0.02, 2.64) 25.0 (0.34, 1832)
Ribeiro et al. (2007) [30] PVS 10 0.71 (0.29, 0,96) 1.00 (0.29, 1.00) 5.5 (0.40, 76.7) 0.36 (0.12, 1.07) 15.4 (0.56, 425.5)
Pooled estimate PVS 65 0.87 (0.70, 0.96) - 3.6 (1.99, 6.6) 0.23 (0.11, 0.50) 23.5 (6.09, 90.9)
Heterogeneity χ2: 2.68; df03 χ2: 4.29; df03 χ2: 0.51; df03 χ2: 1.53; df03 χ2: 0.18; df03
p00.44; Ι2: 0 % p00.23; Ι2: 30 % p00.92; Ι2: 0 % p00.68; Ι2: 0 % p00.98; Ι2: 0 %
Stanley et al. (2004) [16] ASVS 48 0.69 (0.51, 0.83) 0.69 (0.39, 0.91) 2.2 (0.96, 5.2) 0.45 (0.25, 0.84) 4.9 (1.2, 14.7)
Chigot et al. (2001) [31] ASVS 12 0.83 (0.36, 1.00) 0.33 (0.04, 0.78) 1.3 (0.64, 2.4) 0.50 (0.06, 4.2) 2.5 (0.16, 38.6)
Pooled estimate ASVS 60 0.71 (0.55, 0.84) - - 0.46 (0.26, 0.82) 4.3 (1.3, 14.7)
Heterogeneity χ2: 0.59; df01 χ2: 2.18; df01 χ2: 1.46; df01 χ2: 0.01; df01 χ2: 0.19; df01
p00.44; Ι2: 0 % p00.14; Ι2: 54 % p 00 . 2 3 ; Ι 2 :
31 %
p00.93; Ι2: 0 % p00.67; Ι2: 0 %
Hardy et al. (2007) [33] 18F-DOPA PET/CT 50 0.75 (0.53, 0.90) 1.00 (0.87, 1.00) 40 (2.5, 628) 0.26 (0.14, 0.51) 150.9 (8.0, 2845)
Zani et al. (2011) [36] 18F-DOPA PET/CT 19 1.00 (0.77, 1.00) 1.00 (0.48, 1.00) 12 (0.8, 165) 0.04 (0, 0.56) 319.0 (5.6, 18145)
de Lonlay et al. (2006) [29] 18F-DOPA PET 7 1.00 (0.40, 1.00) 1.00 (0.29, 1.00) 7.2 (0.5, 97.8) 0.11 (0.01, 1.63) 63.0 (0.98, 4042)
Barthlen et al. (2008) [32] 18F-DOPA PET 11 0.90 (0.55, 1.00) 1.00 (0.03, 1.00) 3.5 (0.3, 39) 0.18 (0.03, 0.98) 19.0 (0.50, 719.8)
Masue et al. (2011) [34] 18F-DOPA PET/CT 12 0.67 (0.30, 0.93) 1.00 (0.29, 1.00) 5.2 (0.4, 72) 0.40 (0.16, 1.0) 13.0 (0.5, 330.5)
Ribeiro et al. (2007) [30] 18F-DOPA PET/MRI 24 0.93 (0.68, 1.00) 1.00 (0.66, 1.00) 18 (1.2, 271) 0.10 (0.02, 0.46) 183.7 (6.75, 4997)
Otonkoski et al. (2006) [35] 18F-DOPA PET 9 1.00 (0.48, 1.00) 1.00 (0.40, 1.00) 9.2 (0.7, 129) 0.09 (0.01, 1.3) 99.0 (1.62, 6053)
Pooled estimate 18F-DOPA PET 132 - 1.00 (0.93, 1.00) 9.49 (3.5, 26) 0.23 (0.14, 0.37) 73.2 (19.2, 279.7)
Heterogeneity χ2: 12.6; df06 χ2: 0; df06 χ2: 2.44; df06 χ2: 6.09; df06 χ2: 2.69; df06
p00.06; Ι2: 50 % p01.00; Ι2: 0 % p00.88; Ι2: 0 % p00.41; Ι2: 1 % p00.85; Ι2: 0 %
n number of study subject that underwent determinant and subsequent surgical intervention; CT computed tomography; MRI magnetic resonance imaging;
PVS pancreatic venous sampling; ASVS selective pancreatic arterial calcium stimulation with hepatic venous sampling; 18F-DOPA PET ﬂuorine-18L-3,4-
dihydroxyphenylalanine positron emission tomography; LR likelihood ratio; CI conﬁdence interval
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data estimated a localization accuracy of 0.76 (95 % CI;
0.65, 0.85) in detecting the correct location of the focal
lesion in the pancreas.
Two studies reported the localisation accuracy of ASVS.
Included trials reported on a total of 45 patients. Heteroge-
neity was observed between included studies (Ι2017 %, χ20
1.20, df01, p00.27), but was not regarded as clinically
relevant. Pooled data estimated a localization accuracy of
0.64 (95 % CI; 0.49, 0.78).
Trials reporting on 18F-DOPA PET included 84 patients.
Heterogeneity between study results was small (Ι206 %).
Pooled data estimated a localization accuracy of 0.82 (95 %
CI; 0.72, 0.90).
Discussion
CHI is the main cause of persistent hypoglycaemia in
infancy and childhood. Early detection and appropriate
management is crucial for avoiding neurologic complica-
tions. In patients requiring surgery distinguishing focal from
diffuse disease can fundamentally change the surgical
management to focal curative pancreatectomy and near-total
palliative pancreatectomy, respectively. Furthermore, preop-
erative localisation of focal disease is vital for identifying the
focal lesion during curative surgery. Three modalities have
been introduced for these purposes: PVS, ASVS and 18F-






























Fig. 2. Summary ROC curve plotting the true positive rate (sensitivity) against the false-positive rate (1-specificity). Each
symbol represents an individual study in the meta-analysis, with size of the symbol proportional to the sample size of the study.
The open circle represent PVS, the filled upright triangle represents ASVS, and the filled square represents 18F-DOPA PET. The
Q* statistic represents the point where sensitivity and specificity are equal. AUC area under the summary ROC curve, SE
standard error.
Table 5. Localization accuracy; in order of relevance and validity
Author (year) Determinant n Localization accuracy (95% CI)
Capito et al. (2009) [27] PVS 35 0.77 (0.60, 0.90)
Crétolle et al. (2002) [28] PVS 45 0.76 (0.60, 0.87)
Pooled estimate PVS 80 0.76 (0.65, 0.85)
Stanley et al. (2004) [16] ASVS 39 0.62 (0.45, 0.77)
Chigot et al. (2001) [31] ASVS 6 0.83 (0.36, 1.00)
Pooled estimate ASVS 45 0.64 (0.49, 0.78)
Hardy et al. (2007) [33] 18F DOPA PET/CT 24 0.75 (0.53, 0.90)
Zani et al. (2011) [36] 18F DOPA PET/CT 15 0.73 (0.45, 0.92)
Capito et al. (2009) [27] 18F DOPA PET 16 0.81 (0.54, 0.96)
Barthlen et al. (2008) [32] 18F-DOPA PET/CT 10 0.81 (0.55, 1.00)
Ribeiro et al. (2007) [30] 18F-DOPA PET/MRI 15 0.90 (0.66, 1.00)
Otonkoski et al. (2006) [35] 18F-DOPA PET 5 1.00 (0.48, 1.00)
Pooled estimate 18F DOPA PET 84 0.82 (0.72, 0.90)
n number of study subject with focal disease that underwent PVS and subsequent surgical intervention; CI conﬁdence interval; CT computed tomography;
MRI magnetic resonance imaging; PVS pancreatic venous sampling; ASVS selective pancreatic arterial calcium stimulation with hepatic venous sampling; 18F-
DOPA PET ﬂuorine-18L-3,4-dihydroxyphenylalanine positron emission tomography
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modality a systematic review and meta-analysis was
conducted.
Over 1,400 original publications were identiﬁed through
a systematic review of the literature. Of these articles, only
13 articles reported original data on the diagnostic and
localisation accuracy of PVS, ASVS, and/or 18F-DOPA PET
in patients requiring surgery for CHI.
Aside from the sensitivity, 18F-DOPA PET was superior
in every parameter of diagnostic accuracy, including the
parameters that are considered most informative in evaluat-
ing diagnostic accuracy (i.e. positive LR, negative LR,
DOR, AUC, and the Q* statistic; Table 6). Furthermore, 18F-
DOPA PET was found to be superior in localising focal CHI
(pooled localisation accuracy, 0.82) when compared to PVS
(pooled localisation accuracy, 0.76) and ASVS (pooled
localisation accuracy, 0.64).
With an estimated speciﬁcity of 1.00 a positive PET scan
rules in every patient with focal CHI. The possibility of
false-positive results due to F-DOPA accumulation in the
gall bladder and alimentary tract were not observed [37].
The astounding speciﬁcity of 18F-DOPA PET scanning is
further supported by reports detecting focal CHI in ectopic
pancreatic tissue [38, 39].
However, with an estimated sensitivity of 0.75 (range
0.67–1.00), a negative 18F-DOPA PET scan cannot rule
out focal CHI in patients requiring surgery. False-
negative results can occur due to several reasons,
including the inability of small and thin lesions to
accumulate sufﬁcient F-DOPA to be visualized. The
smallest lesion detected by 18F-DOPA PET reported in
the literature has measured 5×4 mm in diameter [35].
Moreover, focal lesions may be missed near the left
kidney, gall bladder, and duodenum due to elimination
of F-DOPA through the kidneys, liver, biliary tract, gall
bladder, and duodenum, especially when focal lesions are
small in size. Localisation accuracy of 18F-DOPA PET
suffered from similar problems.
Besides being diagnostically more accurate, 18F-DOPA
PET has some important additional advantages over both
PVS and ASVS. Most notably, PET scanning is non-
invasive, simple, and remains free of reported complication
in the medical literature.
It must be said, however, that 18F-DOPA PET is not free
of risks. It exposes patients to a small but signiﬁcant fraction
of ionizing radiation, albeit far less than the alternative
angiographic methods. The effective dose of 1 minute of
abdominal ﬂuoroscopy in paediatrics is estimated to be
1 mSv per minute [40]. Since ASVS and PVS procedures
can last up to several hours the accumulative exposure to
ionizing radiation is substantial. Radiation dosimetry from
combined PET/CT, using 80 mAs and 140 kVp for the CT-
scan, is approximately 3 to 5 mSv. The estimated risk of
eventual death from radiation-induced malignancy in paedi-
atrics by an effective dose of 10 mSv was one in 1,000 [41,
42]. Intelligent dose reduction based on the principles of as
low as reasonably achievable is essential for the safest
possible care of children [43].
Developments in the ﬁeld of nuclear medicine, especially
hybrid PET/MRI scanning, could further reduce the radia-
tion burden associated with 18F-DOPA PET scanning and
should—in the near future—be strived for as the ultimate
modality to diagnose and localize CHI [44].
Limitations
Our systematic review and meta-analysis has several limita-
tions. The meta-analysis reported here combined results from
studies with both low and high probability of bias. Further-
more, sample sizes varied greatly among included studies,
where the smallest sample included only four patients [29].
Nevertheless, even when incorporating studies with small
sample sizes, combining the results of multiple studies
increases the diagnostic accuracy of outcome estimates to the
levels that are largely unachievable by stand-alone studies [45].
Furthermore, combining results from multiple studies can
detect homogeneity among their results making estimated
diagnostic accuracy generalizable to other clinics.
Although the majority of included studies reported a
clinically applicable domain, the overall methodological









LR (95 % CI)
Pooled negative
LR (95 % CI)
Summary DOR
(95 % CI)




PVS 0.87 (0.70, 0.96)b 0.73 (0.52, 0.88)a 3.6 (1.99, 6.6) 0.23 (0.11, 0.50) 23.5 (6.09, 90.9) 0.90 (± 0.05) 0.83 (± 0.05) 0.76
(0.65, 0.85)




0.75 (0.53, 0.90)a 1.00 (0.93, 1.00)b 9.49 (3.5, 26)b 0.23 (0.14, 0.37)b 73.2 (19.2, 279.7)b 0.95 (±0.02)b 0.90 (±0.03)b 0.82
(0.72, 0.90)b
CI conﬁdence interval; LR likelihood ratio; DOR diagnostic odds ratio; AUC area under the summary ROC curve; SE standard error; PVS pancreatic venous
sampling; ASVS selective pancreatic arterial calcium stimulation with hepatic venous sampling; 18F-DOPA PET ﬂuorine-18L-3,4-dihydroxyphenylalanine
positron emission tomography
aHeterogeneity among study results. Summary estimate based on a single study of the highest scientiﬁc validity
bValues represents the summary outcome estimate with the highest diagnostic accuracy
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quality of papers was generally poor. The most consistent ﬂaw
in study methodology was insufﬁcient blinding of the assessor
of the reference standard to the outcome of the index test and
vice versa. Only three studies reported sufﬁcient blinding
protocols [16, 32, 33]. Furthermore, a considerable amount of
studies had missing data, either resulting from non-standard-
ized selection of the domain or from a failure to perform the
reference standard on all included patients. Studies with small
sample sizes and high probability of bias tended to overesti-
mate the diagnostic accuracy and could have attributed to the
observed heterogeneity among study results.
Risk of publication bias assessment was considered
inappropriate and not meaningful. Application among meta-
analysis with small number of studies (nG10) yields low
statistical power [46]. Furthermore, large in-between study
heterogeneity could lead to false-positive claims of publication
bias [47]. Both were applicable to our meta-analysis. There-
fore, publication bias assessment was not performed
Despite these limitations, homogeneous study results were
observed for most parameters relating to the diagnostic
accuracy of ASVS, PVS, and 18F-DOPA PET. Therefore, we
feel conﬁdent that the estimated parameters of diagnostic
accuracy approach the levels achieved in a clinical setting.
Nonetheless, the low number of studies included, the low
number of study subjects, and the poor overall methodological
quality of the included studies limit the power of this meta-
analysis in providing strong conclusions and recommenda-
tions. A well-designed cross-sectional trial investigating a large
population of children with CHI should be performed to make
stronger conclusions and recommendations about the diagnos-
tic superiority of 18F-DOPA PET as claimed by the results of
this systematic review and meta-analysis.
Conclusions
In conclusion, this systematic review and meta-analysis
found evidence for the superiority of 18F-DOPA PET in
diagnosing and localizing focal CHI in patients requiring
surgery for this disease. A positive PET scan rules in every
patient with focal CHI. A negative PET scan should,
however, be approached with caution, because false-nega-
tive results tend to occur. As a non-invasive and accurate
modality, 18F-DOPA PET is poised to replace PVS and
ASVS in the diagnostic management of CHI.
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